106 related articles for article (PubMed ID: 21737664)
1. Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy.
Ogawa K; Chiba I; Morioka T; Shimoji H; Tamaki W; Takamatsu R; Nishimaki T; Yoshimi N; Murayama S
Anticancer Res; 2011 Jun; 31(6):2351-9. PubMed ID: 21737664
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between the expression of hypoxia-inducible factor-1alpha and chemotherapy response in esophageal squamous cell carcinoma].
Wu XA; Sun Y; Fan QX; Wang LX; Wang RL
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(25):1783-5. PubMed ID: 17919389
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield S; Bersiga A; Allevi G; Milani M; Aguggini S; Gandolfi V; Dogliotti L; Bottini A; Harris AL; Fox SB
Clin Cancer Res; 2006 Aug; 12(15):4562-8. PubMed ID: 16899602
[TBL] [Abstract][Full Text] [Related]
5. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy.
Kader AS; Lim JT; Berthelet E; Petersen R; Ludgate D; Truong PT
Am J Clin Oncol; 2007 Oct; 30(5):492-7. PubMed ID: 17921709
[TBL] [Abstract][Full Text] [Related]
7. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemoradiotherapy for esophageal cancer with malignant fistula.
Koike R; Nishimura Y; Nakamatsu K; Kanamori S; Shibata T
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1418-22. PubMed ID: 18234437
[TBL] [Abstract][Full Text] [Related]
10. [Expression of hypoxia-inducible factor-1alpha and vessel endothelial growth factor in esophageal squamous cell carcinoma and clinico-pathological significance thereof].
Yu ZT; Zhao HF; Shang XB
Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2465-9. PubMed ID: 19080625
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of p53 and 14-3-3sigma for the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Okumura H; Natsugoe S; Matsumoto M; Yokomakura N; Uchikado Y; Takatori H; Ishigami S; Takao S; Aikou T
J Surg Oncol; 2005 Jul; 91(1):84-9. PubMed ID: 15999354
[TBL] [Abstract][Full Text] [Related]
12. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
[TBL] [Abstract][Full Text] [Related]
13. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Hironaka S; Hasebe T; Kamijo T; Ohtsu A; Boku N; Yoshida S; Saitoh H; Ochiai A
Clin Cancer Res; 2002 Jan; 8(1):124-30. PubMed ID: 11801548
[TBL] [Abstract][Full Text] [Related]
14. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
Akutsu Y; Hanari N; Yusup G; Komatsu-Akimoto A; Ikeda N; Mori M; Yoneyama Y; Endo S; Miyazawa Y; Matsubara H
Ann Surg Oncol; 2011 Oct; 18(10):2946-51. PubMed ID: 21437756
[TBL] [Abstract][Full Text] [Related]
15. [Chemoradiotherapy using platinum analogs/5-FU for advanced esophageal cancer].
Shibata S; Kawasaki H; Nakai M; Morohashi H; Matsuya H; Yamada K; Morita T; Sasaki M
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2209-12. PubMed ID: 12484039
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
Harpole DH; Moore MB; Herndon JE; Aloia T; D'Amico TA; Sporn T; Parr A; Linoila I; Allegra C
Clin Cancer Res; 2001 Mar; 7(3):562-9. PubMed ID: 11297249
[TBL] [Abstract][Full Text] [Related]
17. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.
Kang SY; Han JH; Lee KJ; Choi JH; Park JI; Kim HI; Lee HW; Jang JH; Park JS; Kim HC; Kang S; Oh YT; Chun M; Kim JH; Sheen SS; Lim HY
Clin Cancer Res; 2007 Jul; 13(14):4146-53. PubMed ID: 17634542
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma--a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor.
Chan CM; Ma BB; Hui EP; Wong SC; Mo FK; Leung SF; Kam MK; Chan AT
Oral Oncol; 2007 Apr; 43(4):373-8. PubMed ID: 16979927
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of induction chemotherapy followed by chemo-radiotherapy for patients with advanced cervical esophageal cancer].
Suzuki T; Miura A; Kato T; Izumi Y; Monma K; Kawano T
Gan To Kagaku Ryoho; 2010 Jan; 37(1):71-5. PubMed ID: 20087035
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
